The current status and future prospects of therapeutic drug monitoring of chemotherapy in Jordan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

In the last 20 years, several prospective studies have been conducted to improve the expediency of Therapeutic Drug Monitoring(TDM) application in the field of oncology. However, to start and maintain modern TDM services in developing countries requires more funding and education to reform clinical practices. In the present study, we aimed to determine the current practice of chemotherapy and non-chemotherapy TDM in Jordan. A self-administered questionnaire was developed based on reviews of current state-of-art technology and knowledge with respect to TDM of chemotherapeutic and non-chemotherapeutic agents that are frequently used in oncology. The survey was conducted between December 2009 and February 2010 in two main cancer centers in Jordan. Initial dose individualization based on BSA (96.8%) was indicated as the most common approach. Only 17.5% (n=7) and 67.7% (n=27) of the participants indicated that TDM services are routinely provided for chemotherapeutic or non-chemotherapeutic drugs in cancer patients at their institutions, respectively. The most frequent chemotherapy TDM requests were for methotrexate (n=5) and 5-fluorouracil (n=3), whereas most non-chemotherapy drug level determinations were for tacrolimus (n=22) and cyclosporin (n=22). The majority (83.9%) of respondents acknowledged the unavailability of specialized software for dose adjustment based on computer modeling of observed serum levels. Herein, the evidence presented in this study of low rates for drug concentration monitoring in cancer patients should prompt additional awareness programs of TDM clinical and appropriate economic outcomes, particularly for certain therapeutic regimens of proven value.

Original languageEnglish
Pages (from-to)51-64
Number of pages14
JournalJordan Journal of Pharmaceutical Sciences
Volume5
Issue number1
Publication statusPublished - 19 Jun 2012

Fingerprint

Jordan
Drug Monitoring
Drug Therapy
Neoplasms
Tacrolimus
Methotrexate
Fluorouracil
Pharmaceutical Preparations
Cyclosporine
Developing Countries
Software
Economics
Prospective Studies
Technology
Education
Serum

Keywords

  • Chemotherapy
  • Jordan
  • Multidisciplinary
  • Professional training
  • Therapeutic drug monitoring (TDM)

Cite this

@article{318cd5304d3d4667b147457ffc8e39af,
title = "The current status and future prospects of therapeutic drug monitoring of chemotherapy in Jordan",
abstract = "In the last 20 years, several prospective studies have been conducted to improve the expediency of Therapeutic Drug Monitoring(TDM) application in the field of oncology. However, to start and maintain modern TDM services in developing countries requires more funding and education to reform clinical practices. In the present study, we aimed to determine the current practice of chemotherapy and non-chemotherapy TDM in Jordan. A self-administered questionnaire was developed based on reviews of current state-of-art technology and knowledge with respect to TDM of chemotherapeutic and non-chemotherapeutic agents that are frequently used in oncology. The survey was conducted between December 2009 and February 2010 in two main cancer centers in Jordan. Initial dose individualization based on BSA (96.8{\%}) was indicated as the most common approach. Only 17.5{\%} (n=7) and 67.7{\%} (n=27) of the participants indicated that TDM services are routinely provided for chemotherapeutic or non-chemotherapeutic drugs in cancer patients at their institutions, respectively. The most frequent chemotherapy TDM requests were for methotrexate (n=5) and 5-fluorouracil (n=3), whereas most non-chemotherapy drug level determinations were for tacrolimus (n=22) and cyclosporin (n=22). The majority (83.9{\%}) of respondents acknowledged the unavailability of specialized software for dose adjustment based on computer modeling of observed serum levels. Herein, the evidence presented in this study of low rates for drug concentration monitoring in cancer patients should prompt additional awareness programs of TDM clinical and appropriate economic outcomes, particularly for certain therapeutic regimens of proven value.",
keywords = "Chemotherapy, Jordan, Multidisciplinary, Professional training, Therapeutic drug monitoring (TDM)",
author = "Shilbayeh, {Sireen Abdul Rahim}",
year = "2012",
month = "6",
day = "19",
language = "English",
volume = "5",
pages = "51--64",
journal = "Jordan Journal of Pharmaceutical Sciences",
issn = "1995-7157",
publisher = "The University of Jordan",
number = "1",

}

The current status and future prospects of therapeutic drug monitoring of chemotherapy in Jordan. / Shilbayeh, Sireen Abdul Rahim.

In: Jordan Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19.06.2012, p. 51-64.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The current status and future prospects of therapeutic drug monitoring of chemotherapy in Jordan

AU - Shilbayeh, Sireen Abdul Rahim

PY - 2012/6/19

Y1 - 2012/6/19

N2 - In the last 20 years, several prospective studies have been conducted to improve the expediency of Therapeutic Drug Monitoring(TDM) application in the field of oncology. However, to start and maintain modern TDM services in developing countries requires more funding and education to reform clinical practices. In the present study, we aimed to determine the current practice of chemotherapy and non-chemotherapy TDM in Jordan. A self-administered questionnaire was developed based on reviews of current state-of-art technology and knowledge with respect to TDM of chemotherapeutic and non-chemotherapeutic agents that are frequently used in oncology. The survey was conducted between December 2009 and February 2010 in two main cancer centers in Jordan. Initial dose individualization based on BSA (96.8%) was indicated as the most common approach. Only 17.5% (n=7) and 67.7% (n=27) of the participants indicated that TDM services are routinely provided for chemotherapeutic or non-chemotherapeutic drugs in cancer patients at their institutions, respectively. The most frequent chemotherapy TDM requests were for methotrexate (n=5) and 5-fluorouracil (n=3), whereas most non-chemotherapy drug level determinations were for tacrolimus (n=22) and cyclosporin (n=22). The majority (83.9%) of respondents acknowledged the unavailability of specialized software for dose adjustment based on computer modeling of observed serum levels. Herein, the evidence presented in this study of low rates for drug concentration monitoring in cancer patients should prompt additional awareness programs of TDM clinical and appropriate economic outcomes, particularly for certain therapeutic regimens of proven value.

AB - In the last 20 years, several prospective studies have been conducted to improve the expediency of Therapeutic Drug Monitoring(TDM) application in the field of oncology. However, to start and maintain modern TDM services in developing countries requires more funding and education to reform clinical practices. In the present study, we aimed to determine the current practice of chemotherapy and non-chemotherapy TDM in Jordan. A self-administered questionnaire was developed based on reviews of current state-of-art technology and knowledge with respect to TDM of chemotherapeutic and non-chemotherapeutic agents that are frequently used in oncology. The survey was conducted between December 2009 and February 2010 in two main cancer centers in Jordan. Initial dose individualization based on BSA (96.8%) was indicated as the most common approach. Only 17.5% (n=7) and 67.7% (n=27) of the participants indicated that TDM services are routinely provided for chemotherapeutic or non-chemotherapeutic drugs in cancer patients at their institutions, respectively. The most frequent chemotherapy TDM requests were for methotrexate (n=5) and 5-fluorouracil (n=3), whereas most non-chemotherapy drug level determinations were for tacrolimus (n=22) and cyclosporin (n=22). The majority (83.9%) of respondents acknowledged the unavailability of specialized software for dose adjustment based on computer modeling of observed serum levels. Herein, the evidence presented in this study of low rates for drug concentration monitoring in cancer patients should prompt additional awareness programs of TDM clinical and appropriate economic outcomes, particularly for certain therapeutic regimens of proven value.

KW - Chemotherapy

KW - Jordan

KW - Multidisciplinary

KW - Professional training

KW - Therapeutic drug monitoring (TDM)

UR - http://www.scopus.com/inward/record.url?scp=84862240707&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 51

EP - 64

JO - Jordan Journal of Pharmaceutical Sciences

JF - Jordan Journal of Pharmaceutical Sciences

SN - 1995-7157

IS - 1

ER -